Mary Caffrey

The authors found shifting patterns in the effects of obesity, alcohol, and smoking on atrial fibrillation.

Hospital mergers, drug prices, and non-compete clauses for the rank and file are all targets of President Joe Biden’s pen today as he signed a sweeping executive order instructing federal departments and agencies to reshape what he called “booming” economy by putting workers first, encouraging higher wages and the opportunity for mobility.

A presentation at the 2021 American Society of Clinical Oncology meeting earlier this month reviewed recent findings from trials investigating the treatment of urothelial cancer.

The study, which will be presented next week during the 70th American College of Cardiology Scientific Session, is the first to examine how chest pain is managed among adults who are too young for Medicare.

As hearings of the FDA panel have shown, once a drug is approved and in clinical guidelines, pulling it from the market is not so simple, even if later trials do not confirm phase 2 results.

FDA has recently approved therapies targeting MET exon 14 skipping mutations.

Half the health systems and 65% of doctors had no online reviews, which puts them at a disadvantage when millennials go shopping for healthcare.

Attention is turning this year to heart failure with preserved injection fraction.

The U.S. Circuit Court of Appeals of the District of Columbia ruled Tuesday that the rule could take effect today.

Drug and diagnostic approvals and biosimilars news were popular with readers.

The panel supports an expanded indication but struggles to reach consensus on what an expanded label might look like.

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

Dr. Anthony Fauci addresses the American Heart Association Scientific Sessions.

After an FDA denial and a lost sponsor, sotagliflozin shows it can cut cardiovascular events and possibly treat a form of heart failure that has no approved therapies.

The first in a new class of drugs that targets the cardiac muscle is especially effective in patients with the most serious heart failure.

New data presented recently at the American College of Rheumatology meeting add to the evidence in support of anifrolumab, which could address unmet need in lupus.

Biogen's controversial therapy hits headwinds with panel; stroke indication for Brilinta.

What do the two presidential candidates have right in healthcare policy? Where do they both go wrong? And what will it take for payment reform to take off? Michael Abrams of Numerof discusses what comes after Election Day.

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.

The leading community oncology practice partnership has been an early adopter of biosimilars, and a trouble-shooter for hurdles with payers.

Gilead's Veklury gets full approval; AstraZeneca's Tagrisso heads toward second indication in NSCLC; another use for experimental antifungal therapy.

The legislation follows an investigation that highlighted how minorities experience much higher rates of lower limb amputation than whites.

Prior authorization and other utilization management strategies may cause harmful delays in therapy in oncology and for diseases such as multiple sclerosis, say panelists at PBMI's 4th Annual Specialty Rx Forum.

FDA offers new options in classical Hodgkin lymphoma, and a warning for pregnant women about common pain relievers.

Sodium glucose co-transporter 2 (SGLT2) inhibitors have already remade the diabetes drug market. Now competition for new cardiac and renal indications is heating up among three of the main drugs in the class: Janssen’s Invokana (canagliflozin), AstraZeneca’s Farxiga (dapagliflozin), and Eli Lilly/Boehringer-Ingelheim’s Jardiance (empagliflozin).

The PDUFA date for Alkermes' combination therapy is November 15, 2020.

Results show an electorate deeply divided by age, gender, and partisanship.

William Shrank, MD, MPHS, Humana’s chief medical and corporate affairs officer, said value-based care underscores the need to take a more holistic view of health.

An immunotherapy combination gets a third thoracic indication; another potential indication for an SGLT2 inhibitor.